Market Overview

UPDATE: BMO Capital Markets Reiterates Gilead Sciences at Outperform on Positive ELECTRON Data Results

Share:
Related GILD
Keep An Eye On These 8 After-Hours Movers
Gilead Still A 'Buy' After Harvoni Approval In Japan, Maxim Proclaims
Are Biotechs In A Bubble? (Seeking Alpha)

In a report published Tuesday, BMO Capital Markets reiterated Gilead Sciences Inc. (NASDAQ: GILD) at Outperform on positive ELECTRON data results, and maintained its price target of $89.

BMO Capital Markets noted, "ELECTRON data for the 3-drug all-oral regimen of sofosbuvir + GS-5885 +rbv appear robust with SVR4 of 100% across a fairly representative group of patients with HCV GT1 and importantly in patients with tougher to treat IL28B polymorphisms and across GT1a and GT1b patients. Absence of data in patients with cirrhosis represent one limitation of the ELECTRON data but should be addressed with target enrollment of 20% cirrhotics in phase 3. Based on precedent data from a similar combination of sofosbuvir with BMY's NS5A inhibitor daclatasvir we expect GILD to succeed with a once daily fixed-dose combination of sofosbuvir + GS-5885 without ribavirin and to establish a high barrier to entry. [Our] $89 price target is based on 20x our 2013E EPS of $4.44, discounted 25%, and rate Gilead stock Outperform."

Gilead Sciences closed at $72.69 on Tuesday.

Latest Ratings for GILD

DateFirmActionFromTo
Jul 2015Bank of AmericaMaintainsUnderperform
Apr 2015OppenheimerAssumesOutperform
Feb 2015Credit SuisseDowngradesOutperformNeutral

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Reiteration Analyst Ratings

 

Related Articles (GILD)

Around the Web, We're Loving...

Get Benzinga's Newsletters